OR-502

N/A

Report date: 2023/10/23 20:07:51

Base Information

Drug NameOR-502
Drug Alias NameIgG1 monoclonal antibody that binds specifically to the LILRB2 proteinOR502OR-502
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionLeukocyte immunoglobulin-like receptor subfamily B member 2 binders
TargetsLeukocyte immunoglobulin-like receptor subfamily B member 2
Therapy Area/IndicationsSkin MelanomaSolid tumoursNeoplasm Metastasis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesOncoResponse Inc
China Registration ClassN/A

Develop Information

Active CompaniesOncoResponse Inc
Inactive CompaniesN/A
Active IndicationsSkin MelanomaSolid tumoursNeoplasm Metastasis +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A